BETHESDA, Md., June 21, 2018 (GLOBE NEWSWIRE) — India Globalization Capital, Inc. (NYSE American:IGC) announces financial results for the fiscal year ended March 31, 2018.
“In fiscal 2018, the Company’s focus was to develop, manufacture, and lay the foundation to commercialize our lead product Hyalolex, an alternative oral cannabinoid-based therapy for the treatment of symptoms associated with Alzheimer’s. The commercialization of Hyalolex through medical dispensaries in select states is expected to commence in the second half of calendar 2018. We expect to roll-out our product via licensing arrangements in Puerto Rico and other U.S. states. In the meantime, all our revenue in fiscal 2018 is from our legacy trading business, said Ram Mukunda, CEO.